| https://doi.org/10.82292/fgyv-xh34 |
2017-18 |
Dr Christopher J Burns |
Metabloq Pty Ltd |
High Throughput Screening of Compound Libraries against a Novel Cancer Metabolism Drug Target |
ACRF Drug Discovery Centre for Childhood Cancer |
| https://doi.org/10.82292/rvve-5697 |
2017-18 |
Dr Glen Carter |
Peter Doherty Institute/ BioCurate |
Development of Novel Gut-Targeted Antibiotics for the Treatment of Multidrug-Resistant Pathogens |
Australian Translational Medicinal Chemistry Facility |
| https://doi.org/10.82292/wzqh-3b09 |
2017-18 |
Prof. Spencer Williams |
University of Melbourne |
Pharmacokinetics and distribution of novel non-steroidal asthma drugs |
Centre for Drug Candidate Optimisation |
| https://doi.org/10.82292/k0xg-5z68 |
2017-18 |
Dr Guy Krippner |
Baker IDI |
Novel Receptor Agonists for difficult to treat chronic illness |
Centre for Drug Candidate Optimisation and Australian Translational Medicinal Chemistry Facility |
| https://doi.org/10.82292/762z-0m05 |
2017-18 |
Dr Susie Nilson |
CSIRO |
Toxicology and pharmacokinetic profiling of a stem cell mobilisation agent |
Centre for Drug Candidate Optimisation and TetraQ |
| https://doi.org/10.82292/wqxt-sb11 |
2017-18 |
Dr Natalie Borg |
Monash University |
A broad-spectrum antiviral target and anticancer target |
Compounds Australia |
| https://doi.org/10.82292/b618-eg41 |
2017-18 |
Prof. Charles Mackay |
Monash University |
Developing an agonistic antibody |
Monash Antibody Technologies Facility |
| https://doi.org/10.82292/fkj2-h317 |
2017-18 |
Prof. Rajiv Khanna |
QIMR Berghofer |
The establishment of a repository of in vitro-expanded T cells for the treatment of viral complications in transplant recipients |
Q-Gen Cell Therapeutics (QIMR Berghofer) |
| https://doi.org/10.82292/sf5c-xp13 |
2019-20 (Core facilities) |
Prof Tom Gonda |
University of South Australia |
Development of a small molecule inhibitor of the MYB oncogene as a therapeutic for Acute Myeloid Leukaemia |
Australian Translational Medicinal Chemistry Facility |
| https://doi.org/10.82292/ek2g-8m20 |
2019-20 (Core facilities) |
Mr Gregory Santamaria |
Cyclotek (Aus) Pty Ltd |
Development of advanced and novel radioligands for Positron Emission Tomography (PET) imaging |
Australian Translational Medicinal Chemistry Facility |
| https://doi.org/10.82292/wdt2-hx72 |
2019-20 (Core facilities) |
Dr Steven Petratos |
Monash University |
Development of Small Molecules to Promote Remyelination in Multiple Sclerosis |
Australian Translational Medicinal Chemistry Facility |
| https://doi.org/10.82292/430v-ha46 |
2019-20 (Core facilities) |
Dr David Elliott |
Murdoch Children’s Research Institute |
Identifying compounds that protect against anthracycline induced heart damage |
Australian Translational Medicinal Chemistry Facility |
| https://doi.org/10.82292/5wd0-w063 |
2019-20 (Core facilities) |
Dr Wim Meutermans |
Vast Bioscience Pty Ltd |
ADME and PK evaluation of VAST preclinical candidates for postsurgical pain |
Centre for Drug Candidate Optimisation |
| https://doi.org/10.82292/hkcc-5y29 |
2019-20 (Core facilities) |
Prof Katherine Andrews |
Griffith Institute for Drug Discovery (GRIDD) |
Pre-clinical optimisation studies on a new antimalarial drug lead |
Centre for Drug Candidate Optimisation |
| https://doi.org/10.82292/ryn7-ha77 |
2019-20 (Core facilities) |
Dr Ebony Fietz |
Gertrude Biomedical Pty Ltd |
Preclinical ADME and PK drug properties of novel inhibitors of SOX18 transcription factor |
Centre for Drug Candidate Optimisation |
| https://doi.org/10.82292/kdvn-cc47 |
2019-20 (Core facilities) |
Prof Bernard Flynn |
Monash University |
Targeting Sphingosine Kinase 1 for the Treatment of Pulmonary Hypertension |
Centre for Drug Candidate Optimisation and TetraQ |
| https://doi.org/10.82292/jsk5-ex93 |
2019-20 (Core facilities) |
Dr Nicholas Veldhuis |
Monash University |
Assessing efficacy of analgesic nanoparticles in chemotherapy-induced neuropathic pain |
Centre for Integrated Preclinical Drug Development |
| https://doi.org/10.82292/nyyv-rp89 |
2019-20 (Core facilities) |
A/Prof Brendon Coventry |
Cancuravax Pty Ltd |
Melanoma Cancer Vaccine Immunotherapy Production & Scaling for Commercialisation |
National Biologics Facility NSW Node |
| https://doi.org/10.82292/we6x-j896 |
2019-20 (Core facilities) |
Dr Brad Walsh |
GlyTherix Ltd |
Production and Lead Selection of Humanised Anti-Glypican-1 Antibodies |
National Biologics Facility NSW Node |
| https://doi.org/10.82292/zjbc-5h19 |
2019-20 (Core facilities) |
Kevin Isch |
NeuClone Pty Ltd |
Development and validation of an ECL immunoassay method for quantitation of ustekinumab concentration in human serum |
TetraQ |
| https://doi.org/10.82292/3xq0-6w79 |
2019-20 (Screening) |
Prof Brian Gabrielli |
TRI |
Screen for new agents to selectively kill a novel defect in melanomas |
ACRF Drug Discovery Centre for Childhood Cancer |
| https://doi.org/10.82292/q4y3-wk08 |
2019-20 (Screening) |
Dr Joseph Brock |
ANU |
Development of an engineered thermal shift assay for the high-throughput discovery of integral membrane protein lead compounds |
ANU Centre for Therapeutic Discovery |
| https://doi.org/10.82292/heze-9j85 |
2019-20 (Screening) |
Dr Amee George |
ANU |
Identifying therapeutics for the treatment of Myelodysplastic Syndrome |
ANU Centre for Therapeutic Discovery |
| https://doi.org/10.82292/ysy8-g459 |
2019-20 (Screening) |
Prof Si Ming Man |
ANU |
Novel antitoxin compound discovery for the treatment of antibiotic resistant bacteria |
ANU Centre for Therapeutic Discovery |
| https://doi.org/10.82292/a01f-y528 |
2019-20 (Screening) |
Dr Nicholas Eyre |
University of Adelaide |
Development of inhibitors of dengue virus (DENV) NS1 protein dimerization as novel antiviral therapeutics |
Cell Screen SA |
| https://doi.org/10.82292/k56b-4a93 |
2019-20 (Screening) |
Dr Benjamin Blasco |
GARDP |
The discovery and development of novel antibiotics against MDR and XDR Gram-negative pathogens |
CO-ADD |
| https://doi.org/10.82292/mpdd-h569 |
2019-20 (Screening) |
Ms Natasa Broit |
QIMR Berghofer |
Identification of novel therapies for the treatment of acral lentiginous melanoma |
Griffith Discovery Biology |
| https://doi.org/10.82292/bt01-mp70 |
2019-20 (Screening) |
Dr Brian Dymock |
UniQuest |
Identification of Inhibitors of a key oncogenic protein by Fragment Screening |
Monash Fragment Platform |
| https://doi.org/10.82292/6q6s-2e28 |
2019-20 (Screening) |
Dr Nicholas Clemons |
Peter MacCallum Cancer Institute |
A specific inhibitor of SLC7A11 (XCT) for single agent or combination treatment of cancers with mutant p53 |
Victorian Centre for Functional Genomics |
| https://doi.org/10.82292/8pan-sd75 |
2019-20 (Screening) |
Dr Kathleen Pishas |
Peter MacCallum Cancer Institute |
Defining the role of clonal interaction in high grade serous ovarian cancer drug resistance |
Victorian Centre for Functional Genomics |
| https://doi.org/10.82292/4r6x-5v90 |
2019-20 (Screening) |
Dr Dane Cheasley |
Peter MacCallum Cancer Institute |
High throughput investigation of synergistic drug combinations for patients with low-grade serous ovarian carcinoma |
Victorian Centre for Functional Genomics |
| https://doi.org/10.82292/zt8m-n327 |
2019-20 (Screening) |
Dr Michael Sharp |
St. Vincent’s Institute of Medical Research |
Inhibiting the Fanconi Anaemia pathway to target BRCA1/2 negative breast and ovarian cancers |
Victorian Centre for Functional Genomics |
| https://doi.org/10.82292/c6za-fg83 |
2020 COVID-19 |
Dr Arun Konagurthu |
Monash University |
Modelling, synthesis and testing of potential agents against COVID-19 main protease |
Australian Translational Medicinal Chemistry Facility |
| https://doi.org/10.82292/fbdd-8x59 |
2020 COVID-19 |
Dr Charles Bailey |
Centenary Institute |
Monitoring the therapeutic efficacy of BD-218, a human neutralising monoclonal antibody against SARS-CoV-2, in COVID-19 patients using Nanostring gene expression analysis |
Cell & Molecular Therapies |
| https://doi.org/10.82292/arkh-1133 |
2020 COVID-19 |
Prof Bevyn Jarrott |
Vailima Peninsula Pty Ltd |
Pre-clinical development of a novel, patented small molecule to treat COVID-19 respiratory injury |
Centre for Drug Candidate Optimisation |
| https://doi.org/10.82292/0rjv-pk12 |
2020 COVID-19 |
Dr Richard Angell |
University College London |
Using fragment-based drug discovery to identify small molecule inhibitors of SARS-CoV-2 (COVID-19) RNA-dependent RNA polymerase (RdRp) and future starting points for other Coronaviruses |
Monash Fragment Platform |
| https://doi.org/10.82292/5dsd-4g64 |
2020 COVID-19 |
Prof Terrance Johns |
Telethon Kids Institute |
Discovery of antibodies to the furin cleavage site of SARS-CoV-2 Spike Glycoprotein |
National Biologics Facility Queensland Node |
| https://doi.org/10.82292/f7fc-cm44 |
2020 COVID-19 |
A/Prof Severine Navarro |
QIMR Berghofer Medical Research Institute |
Prevention of COVID-19-induced hyperinflammatory syndrome with the immunomodulatory protein AIP-2” |
National Biologics Facility Queensland Node |
| https://doi.org/10.82292/bvy8-na90 |
2020 COVID-19 |
Dr Keith Dredge |
Zucero Therapeutics Ltd |
Analytical and bioanalytical development of pixatimod (ZU545/PG545)- a clinical candidate for cancer with anti-viral and anti-inflammatory properties - to support clinical testing for Covid-19” |
TetraQ |
| https://doi.org/10.82292/yks2-cn38 |
2020 COVID-19 |
Dr Cameron Stewart |
Australian Centre for Disease Prevention (ACDP), CSIRO |
Defining the role of host microRNAs in COVID-19” |
Victorian Centre for Functional Genomics |
| https://doi.org/10.82292/jp96-pz29 |
2020-21 (Round 1) |
Prof. Ian Smyth |
Monash University |
Inhibiting cystogenesis in Polycystic Kidney Disease with AURKA PROTACs |
Australian Translational Medicinal Chemistry Facility |
| https://doi.org/10.82292/4m39-h714 |
2020-21 (Round 1) |
Dr Mark Del Borgo |
Monash University |
Synthesis of novel peptide mimics for use as anti-fibrotic agents |
Australian Translational Medicinal Chemistry Facility |
| https://doi.org/10.82292/rcap-jg76 |
2020-21 (Round 1) |
Prof. Alastair Stewart |
Tianli Biotech Pty Ltd |
Development of casein kinase 1 delta inhibitors for inflammation, fibrosis and fibrotic cancers |
Centre for Drug Candidate Optimisation |
| https://doi.org/10.82292/cppe-ws05 |
2020-21 (Round 1) |
Dr. Christopher Burns |
MycRx Pty Ltd |
Novel, small-molecule therapeutics for the treatment of cancers addicted to the oncoprotein Myc |
Centre for Drug Candidate Optimisation |
| https://doi.org/10.82292/83rz-6a28 |
2020-21 (Round 1) |
Dr Michael Thurn |
Botanix Pharmaceuticals |
Studies of Bacterial Resistance Induced by Cannabidiol (CBD) |
CO-ADD |
| https://doi.org/10.82292/racg-1y66 |
2020-21 (Round 1) |
Dr. Fernando S. F. Guimaraes |
University of Queensland |
Development of new anti-breast cancer antibodies for natural killer (NK) cell-based immunotherapy |
National Biologics Facility Queensland Node |
| https://doi.org/10.82292/33k4-8a30 |
2020-21 (Round 1) |
Prof. Alex Loukas |
James Cook University |
Innovative IBD biologics inspired by host-parasite coevolution |
National Biologics Facility Queensland Node |
| https://doi.org/10.82292/h5z5-zs57 |
2020-21 (Round 1) |
Prof. John Hooper |
Mater Research Institute |
Screening for a manufacturable antibody variant for PET-CT imaging of ovarian cancer |
National Biologics Facility Queensland Node |
| https://doi.org/10.82292/gz6e-xa19 |
2020-21 (Round 1) |
Prof. Peter Timms |
University of Sunshine Coast |
Development of a chlamydial vaccine for koalas: Production of chlamydial proteins at high quality suitable for vaccine trials |
National Biologics Facility Victoria Node |
| https://doi.org/10.82292/xdjj-az48 |
2020-21 (Round 1) |
Dr. Brad Walsh |
Glytherix Ltd |
Optimisation and Characterisation of Miltuximab-DFO Bioconjugation |
National Biologics Facility Victoria Node |
| https://doi.org/10.82292/3n7f-na05 |
2020-21 (Round 1) |
Prof. Andrew Prowse |
University of Queensland |
Pilot scale GMP production of cardiomyocytes derived from human pluripotent stem cells |
Q-Gen Cell Therapeutics (QIMR Berghofer) |
| https://doi.org/10.82292/ad6r-m163 |
2020-21 (Round 1) |
Dr Stuart Fraser |
University of Sydney |
Nanions: a rapid, non-toxic nanoparticle vaccine platform |
TetraQ |
| https://doi.org/10.82292/jgzw-wk34 |
2020-21 (Round 1) |
Prof. Suddha Rao |
QIMR Berghofer Medical Research Institute |
Safety and pharmacokinetics study of a novel anti-PD-L1 therapeutic to improve immunotherapy in triple-negative breast cancer |
TetraQ |
| https://doi.org/10.82292/mvfh-3q50 |
2020-21 (Round 1) |
Prof. Mark von Itzstein |
Griffith University |
Preclinical development of a drug lead candidate against human parainfluenza virus – Exploratory pharmacokinetic, toxicity, and metabolic studies |
TetraQ and Centre for Drug Candidate Optimisation |
| https://doi.org/10.82292/x2jd-zp37 |
2020-21 (Round 1) Screening |
Prof. Ian Street |
Children's Cancer Institute |
Development of a high-throughput screening assay for a novel activated kinase ALPK1 |
ACRF Drug Discovery Centre for Childhood Cancer |
| https://doi.org/10.82292/hn16-tr22 |
2020-21 (Round 1) Screening |
A/Prof Marco Casarotto |
Australian National University |
Developing therapeutics that treat/prevent ischemia reperfusion injury (IRI) |
ANU Centre for Therapeutic Discovery |
| https://doi.org/10.82292/8vrj-gg45 |
2020-21 (Round 1) Screening |
Assoc. Prof. Leonie Quinn |
Australian National University |
High-Throughput 3D Cell and Organism Screening for new brain cancer (glioma) treatments |
ANU Centre for Therapeutic Discovery |
| https://doi.org/10.82292/bkxp-dq96 |
2020-21 (Round 1) Screening |
Prof. Sally-Ann Poulsen |
Griffith University |
Restoring the efficacy of chemotherapy in drug resistant cancers |
Griffith Discovery Biology |
| https://doi.org/10.82292/vqce-2a41 |
2020-21 (Round 1) Screening |
Prof. Murray Whitelaw |
University of Adelaide |
Discovery and development of new antimicrobials to combat antibiotic resistance |
GRIDD Mass Spectrometry Screening |
| https://doi.org/10.82292/1z7m-4v02 |
2020-21 (Round 1) Screening |
Dr Shom Goel |
Peter MacCallum Cancer Centre |
Improving outcomes for breast cancer patients receiving CDK4/6 inhibitors |
Victorian Centre for Functional Genomics |
| https://doi.org/10.82292/e34x-dg73 |
2020-21 (Round 1) Screening |
Dr. Eleanor Saunders |
University of Melbourne |
Targeting human leishmaniasis |
Victorian Centre for Functional Genomics |
| https://doi.org/10.82292/mhyv-kp21 |
2020-21 (Round 2) |
Dr Mitali Sarkar-Tyson |
University of Western Australia |
Advanced development of therapeutics against bacterial pathogens of biowarfare concern |
Australian Translational Medicinal Chemistry Facility |
| https://doi.org/10.82292/wqeb-0y94 |
2020-21 (Round 2) |
A/Prof Daniel Thomas |
University of Adelaide |
Iterative design of selective Type II JAK2 Inhibitor for superior management of myelofibrosis |
Australian Translational Medicinal Chemistry Facility |
| https://doi.org/10.82292/rrrd-7171 |
2020-21 (Round 2) |
Dr Chengxue Helena Qin |
Monash University |
Next generation formyl peptide receptor 2 agonists to treat pulmonary hypertension |
Australian Translational Medicinal Chemistry Facility |
| https://doi.org/10.82292/0tv1-yt05 |
2020-21 (Round 2) |
Dr Nadia Warner |
Peter Doherty Institute for Infection and Immunity |
Synthesis and development of targeted degraders of the hepatitis B virus (HBV) core proteins for HBV therapy |
Australian Translational Medicinal Chemistry Facility |
| https://doi.org/10.82292/qwch-v272 |
2020-21 (Round 2) |
Dr Paul Stupple |
CTx/Monash University |
In vivo and in vitro pharmacokinetic studies of novel therapeutics against blood cancers |
Centre for Drug Candidate Optimisation |
| https://doi.org/10.82292/cgp4-vr86 |
2020-21 (Round 2) |
Dr Mark Devlin |
Aculeus Therapeutics Pty Ltd |
Systemically delivered small molecule STING agonists as next generation cancer immunotherapies |
Centre for Drug Candidate Optimisation |
| https://doi.org/10.82292/v22q-gc78 |
2020-21 (Round 2) |
Dr Chris Langmead |
Monash University |
Development of biased agonists for schizophrenia |
Centre for Drug Candidate Optimisation and Australian Translational Medicinal Chemistry Facility |
| https://doi.org/10.82292/px16-ea35 |
2020-21 (Round 2) |
Dr Pegah Varamini |
University of Sydney |
Development of novel therapeutics for targeted therapy of triple negative breast cancer |
Centre for Integrated Preclinical Drug Development |
| https://doi.org/10.82292/ccsp-n477 |
2020-21 (Round 2) |
Dr Julian Barden |
Biosceptre Aust Pty Ltd |
Development of novel cellular cancer therapeutics |
National Biologics Facility NSW Node |
| https://doi.org/10.82292/4g19-6b52 |
2020-21 (Round 2) |
A/Prof Ashley Buckle |
Monash University |
Development of novel anti-inflammatory biologics |
National Biologics Facility Queensland Node |
| https://doi.org/10.82292/e4d4-6y80 |
2020-21 (Round 2) |
Prof Elizabeth Coulson |
University of Queensland |
Therapeutic antibody discovery to block neurotrophin receptor cleavage |
National Biologics Facility Queensland Node |
| https://doi.org/10.82292/dh48-dy71 |
2020-21 (Round 2) Screening |
A/Prof Ian Street |
Children's Cancer Institute |
Development of an assay system to identify CNS-penetrant derivatives of pre-existing drugs for brain cancer |
ACRF Drug Discovery Centre for Childhood Cancer |
| https://doi.org/10.82292/ej2n-6y69 |
2020-21 (Round 2) Screening |
Prof Klaus-Martin Schulte |
Australian National University |
Identifying therapeutics for the treatment of advanced BRCA2 breast cancer” |
ANU Centre for Therapeutic Discovery |
| https://doi.org/10.82292/3th3-pc66 |
2020-21 (Round 2) Screening |
Prof Mark Dawson |
Peter MacCallum Cancer Centre |
Identification of novel immune-checkpoint therapies to inhibit interaction between PD-L1 and CMTM6, a new regulator of anti-tumour immunity |
Griffith Discovery Biology |
| https://doi.org/10.82292/m6n8-j063 |
2020-21 (Round 2) Screening |
Dr Jess Tiffen |
Centenary Institute |
Identifying Epigenetic Drivers of Drug Resistant Melanoma |
Griffith Discovery Biology |
| https://doi.org/10.82292/eh05-1n71 |
2020-21 (Round 2) Screening |
A/Prof Ethan D. Goddard-Borger |
WEHI |
Developing fucosyltransferase inhibitors as treatments for rare leukaemia |
Monash Fragment Platform |
| https://doi.org/10.82292/zmv7-0d15 |
2020-21 (Round 2) Screening |
Prof Frederic Hollande |
University of Melbourne |
Developing a combined small molecule and immune cell killing assay to identify new therapeutics in pancreatic cancer” |
Victorian Centre for Functional Genomics |
| https://doi.org/10.82292/vaha-4449 |
2021-22 (Round 1) |
Prof Ian Smyth |
Monash University |
Inhibiting cyst formation in polycystic kidney disease with targeted protein degraders (TPDs) |
Australian Translational Medicinal Chemistry Facility |
| https://doi.org/10.82292/fb56-v382 |
2021-22 (Round 1) |
A/Prof Nick Clemons |
Peter MacCallum Cancer Centre |
Synthesis of novel small molecule inhibitors of SLC7A11/XCT for mutant-p53 cancers |
Australian Translational Medicinal Chemistry Facility |
| https://doi.org/10.82292/78nj-5y69 |
2021-22 (Round 1) |
Dr Robert Feldman |
COVID-19 Vaccine Corporation |
Development of an mRNA cytotoxic T-cell COVID-19 vaccine |
BASE Facility |
| https://doi.org/10.82292/qene-q522 |
2021-22 (Round 1) |
A/Prof Jonathan S. Oakhill |
St Vincent's Institute of Medical Research |
Development of CaMKK2 inhibitors as new cancer therapies |
Centre for Drug Candidate Optimisation |
| https://doi.org/10.82292/039z-zw14 |
2021-22 (Round 1) |
Dr Willem Joost Lesterhuis |
Telethon Kids Institute |
Development of small molecule drugs in immuno-oncology |
Centre for Drug Candidate Optimisation |
| https://doi.org/10.82292/1kte-3j11 |
2021-22 (Round 1) |
Dr Samantha South |
Argenica Therapeutics Ltd |
Neuroprotective efficacy of poly-argine-18 (R18) in a relapsing-remitting experimental autoimmune encephalomyelitis (RR-EAE) mouse model of multiple sclerosis (MS) |
Centre for Integrated Preclinical Drug Development |
| https://doi.org/10.82292/bbkh-7961 |
2021-22 (Round 1) |
Dr Ben Rollo |
Monash University |
Human high-throughput in-vitro phenotypic screening for new epilepsy drugs |
Compounds Australia |
| https://doi.org/10.82292/f7y7-dg28 |
2021-22 (Round 1) |
Prof Sudha Rao |
QIMR Berghofer |
Identification of a small molecule inhibitor for therapeutic targeting of a novel nuclear methyltransferase in immunotherapy-resistant metastatic cancers |
GRIDD Mass Spectrometry Screening |
| https://doi.org/10.82292/942k-5h71 |
2021-22 (Round 1) |
A/Prof Jenny Gunnersen |
University of Melbourne |
Screening for therapeutic antibodies to treat chronic pain |
National Biologics Facility Queensland Node |
| https://doi.org/10.82292/6q9k-tv80 |
2021-22 (Round 1) |
Prof John Hooper |
Mater Research Institute |
Process development to optimise and characterise the conjugation process of DFO and monoclonal antibody 10D7 |
National Biologics Facility Victoria Node |
| https://doi.org/10.82292/whba-j504 |
2021-22 (Round 1) |
Dr Nicholas Hunt |
University of Sydney |
Synthesis and characterisation of Ag2S quantum dots and conjugation to insulin at CSIRO |
National Biologics Facility Victoria Node |
| https://doi.org/10.82292/kw2f-8110 |
2021-22 (Round 1) |
Dr Chisha Teza Sikazwe |
PathWest Laboratory Medicine WA |
Development of recombinant MVEV and JEV NS1 antigen for the detection of JEV and MVEV antibody in serum |
Protein Expression Facility |
| https://doi.org/10.82292/amqc-ww10 |
2021-22 (Round 1) |
Prof Rajiv Khanna |
QIMR Berghofer |
The establishment of a repository of in vitro-expanded cytomegalovirus-specific T cells for the treatment of glioblastoma multiforme |
Q-Gen Cell Therapeutics (QIMR Berghofer) |
| https://doi.org/10.82292/kst8-nc49 |
2021-22 (Round 1) |
Prof John EJ Rasko |
Centenary Institute |
Novel gene therapy platforms for hemophilia B |
Vector and Genome Engineering Facility |
| https://doi.org/10.82292/eqm2-hx66 |
2021-22 (Round 1) |
Dr Gonzalo Perez-Siles |
ANZAC Research Institute |
Development of a high throughput screening platform of patient-derived iPSC motor neuron for enhancers of energy metabolism as a therapeutic intervention in axonal degeneration |
Victor Chang Cardiac Research Institute |
| https://doi.org/10.82292/rpkh-4062 |
2021-22 (Round 1) |
Dr Marie Besnier |
University of Sydney |
Treating the mitochondria to improve endothelial function of patients with coronary artery disease |
Victor Chang Cardiac Research Institute |
| https://doi.org/10.82292/tpq5-vs48 |
2021-22 (Round 1) |
Dr Mitchell Lawrence |
Monash University |
New generation combination therapies for advanced prostate cancer |
Victorian Centre for Functional Genomics |
| https://doi.org/10.82292/d71k-1f86 |
2021-22 (Round 2) |
Prof Christopher Langmead |
Monash Institute of Pharmaceutical Sciences |
Development of novel agonists for schizophrenia |
Australian Translational Medicinal Chemistry Facility |
| https://doi.org/10.82292/jvaa-wt45 |
2021-22 (Round 2) |
Dr Thomas Theodor Tapmeier |
Monash University |
NPSR1 Antagonist in Endometriosis |
Australian Translational Medicinal Chemistry Facility |
| https://doi.org/10.82292/kqk7-9y94 |
2021-22 (Round 2) |
Prof Ian Smyth |
Monash University |
Pharmacokinetic Assessments and optimisation of a new therapy for PKD |
Australian Translational Medicinal Chemistry Facility and Centre for Drug Candidate Optimisation |
| https://doi.org/10.82292/qtp6-q395 |
2021-22 (Round 2) |
Dr William Thomas Jorgensen |
Psylo Pty Ltd |
Pre-clinical development of novel serotonergic agents for therapeutic applications in mental illness |
Centre for Drug Candidate Optimisation |
| https://doi.org/10.82292/9x7g-6526 |
2021-22 (Round 2) |
Dr Sohinee Sarkar |
Murdoch Children's Research Institute |
A new treatment for the cystic fibrosis superbug, Mycobacteroides abscessus |
Compounds Australia |
| https://doi.org/10.82292/pdk6-cq90 |
2021-22 (Round 2) |
Dr Nicole Van Bergen |
Murdoch Children’s Research Institute |
Utilising high-throughput drug screening for mitochondrial metabolite repair disorders |
Compounds Australia |
| https://doi.org/10.82292/rv6t-qq90 |
2021-22 (Round 2) |
Dr Katherine Locock |
CSIRO |
Accelerated antibiotic discovery through high-throughput |
Compounds Australia and Community for Open Antimicrobial Drug Discovery |
| https://doi.org/10.82292/04xr-kd12 |
2021-22 (Round 2) |
Prof Kristen Radford |
Mater Research Institute |
Development of human CLEC9A antibodies as cancer vaccines |
National Biologics Facility Queensland Node |
| https://doi.org/10.82292/t22t-3k37 |
2021-22 (Round 2) |
A/Prof Rebecca Lim |
Prescient Therapeutics |
Preclinical toxicity studies for OmniCAR-enabled targeting ligands |
National Biologics Facility Queensland Node |
| https://doi.org/10.82292/8vfk-gq55 |
2021-22 (Round 2) |
Dr Sarah Jones |
Monash University |
A novel Glucocorticoid (GC) mimic for the treatment of inflammatory and autoimmune diseases |
National Biologics Facility Victoria Node |
| https://doi.org/10.82292/vrwd-vv53 |
2021-22 (Round 2) |
A/Prof Rebecca Lim |
Hudson Institute of Medical Research |
Phase II Amnion Cell Therapy in Ischemic Stroke |
Q-Gen Cell Therapeutics (QIMR Berghofer) |
| https://doi.org/10.82292/jwff-wh96 |
2021-22 (Round 2) |
Prof Timothy Stinear |
University of Melbourne |
A high-throughput screening campaign to find inhibitors of intracellular multi-drug resistant Staphylococcus aureus |
Victorian Centre for Functional Genomics |
| https://doi.org/10.82292/kxqp-pe64 |
2021-22 (Round 2) |
A/Prof Kara Britt |
Peter MacCallum Cancer Centre |
Identify drugs that selectively inhibit oestrogen receptor positive luminal progenitor activity |
Victorian Centre for Functional Genomics |
| https://doi.org/10.82292/nx3m-yj92 |
2022-23 (Round 1) |
Prof Philip Board |
Omega-One Therapeutics Pty. Ltd. |
Developing Glutathione transferase Omega 1 inhibitors as anti-inflammatory therapeutics |
Australian Translational Medicinal Chemistry Facility |
| https://doi.org/10.82292/zmv0-kz47 |
2022-23 (Round 1) |
Prof Enzo Porrello |
Murdoch Children's Research Institute |
Developing next generation cardio-regenerative therapeutics to treat systolic heart failure |
Australian Translational Medicinal Chemistry Facility |
| https://doi.org/10.82292/nb9c-p530 |
2022-23 (Round 1) |
Prof Mark von Itzstein |
Institute for Glycomics, Griffith University |
Development of drug candidates against drug resistant bacteria |
Centre for Drug Candidate Optimisation |
| https://doi.org/10.82292/fc3p-vs14 |
2022-23 (Round 1) |
Ms Filippa Shub |
Inosi Therapeutics |
IRAP inhibitor lead optimisation |
Centre for Drug Candidate Optimisation |
| https://doi.org/10.82292/sje9-sd81 |
2022-23 (Round 1) |
Prof Brian Gabrielli |
Mater Research Institute |
Screen for compounds synthetically lethal with defective RB and p53 |
Griffith Discovery Biology |
| https://doi.org/10.82292/6m3f-t539 |
2022-23 (Round 1) |
Prof Alastair Stewart |
University of Melbourne |
Discovery of selective inhibitors for fibrosis |
Monash Fragment Platform |
| https://doi.org/10.82292/407e-8568 |
2022-23 (Round 1) |
Dr Jacek Kwiatkowski |
Queensland Emory Drug Discovery Initiative |
Identification of Inhibitors of a Key Necroptotic Protein Through Fragment Screening |
Monash Fragment Platform |
| https://doi.org/10.82292/aewt-4120 |
2022-23 (Round 1) |
Mr Robert Batchelor |
Nutromics Pty Ltd |
Surface plasmon resonance-based screening of DNA aptamers targeted to small molecule drugs |
Monash Fragment Platform |
| https://doi.org/10.82292/0xas-sy75 |
2022-23 (Round 1) |
A/Prof Daniel Thomas |
University of Adelaide |
Anti-mutant CALR Antibody Preparation for Clinical Manufacture for Patients with Myelofibrosis |
National Biologics Facility Queensland Node |
| https://doi.org/10.82292/381q-mx16 |
2022-23 (Round 1) |
Mr Paul Fahey |
Vaxxas Pty. Ltd. |
Enhanced skin delivery of vaccines by manipulating surface interactions on High Density Micro Array Patches (HD-MAP’s). |
National Biologics Facility Victoria Node |
| https://doi.org/10.82292/h0ah-jd02 |
2022-23 (Round 1) |
Dr Graham Heery |
Starpharma Pty Ltd |
Production of a HER2 binding nanobody for the assembly of targeted novel dendrimer therapeutics for breast and gastric cancer |
Protein Expression Facility |
| https://doi.org/10.82292/ym35-5439 |
2022-23 (Round 1) |
Dr Steve Dingwall |
Australian Institute for Bioengineering and Nanotechnology |
Generation of Induced Pluripotent Stem Cell Master and Working Cell Banks for a Phase 1 Clinical Trial for the Treatment of Heart Failure |
Q-Gen Cell Therapeutics (QIMR Berghofer) |
| https://doi.org/10.82292/22fq-g666 |
2022-23 (Round 1) |
Prof James St John |
Griffith University |
Spinal Injury Project: pilot-scale GMP production and validation of clinically compliant nerve bridges |
Q-Gen Cell Therapeutics (QIMR Berghofer) |
| https://doi.org/10.82292/2ke6-n640 |
2022-23 (Round 1) |
Prof Andrew Elefanty |
Murdoch Children's Research Institute |
Building a better leukaemia – Modeling paediatric acute myeloid leukaemia in pluripotent stem cells |
Stafford Fox Drug Discovery Facility |
| https://doi.org/10.82292/2vxe-g490 |
2022-23 (Round 1) |
A/Prof Silvia Velasco |
Murdoch Children's Research Institute |
Development of a platform for the automated generation and high-throughput drug screening of brain organoids |
Stafford Fox Drug Discovery Facility |
| https://doi.org/10.82292/kk94-5x14 |
2022-23 (Round 1) |
Prof Robyn Jamieson |
Children's Medical Research Institute |
Long-term AAV-mediated genetic rescue of photoreceptors in retinitis pigmentosa |
Sydney Cell and Gene Therapy |
| https://doi.org/10.82292/a4tf-4810 |
2022-23 (Round 1) |
A/Prof James Chong |
Westmead Institute for Medical Research |
Process development for the preparation and delivery of induced pluripotent stem cell derived cardiomyocytes for end stage heart failure. |
Sydney Cell and Gene Therapy |
| https://doi.org/10.82292/z4y9-1t06 |
2022-23 (Round 1) |
A/Prof Elaine Sanij |
St Vincent's Institute of Medical Research |
Development of new cancer therapeutics targeting the nucleoli |
Victorian Centre for Functional Genomics |
| https://doi.org/10.82292/zgtp-y291 |
2022-23 (Round 1) Technical Feasibility Assessment |
Dr Rhonda Taylor |
The University of Western Australia (UWA) |
Allele-selective CRISPR deletion as a therapy for ACTA1 congenital myopathy |
Cell & Tissue Therapies WA |
| https://doi.org/10.82292/3se1-yn33 |
2022-23 (Round 1) Technical Feasibility Assessment |
A/Prof Anthony Kicic |
Telethon Kids Institute |
Making bacteriophage therapy a reality: Implementation of a novel treatment pipeline to treat antimicrobial-resistant infections. |
Cell & Tissue Therapies WA |
| https://doi.org/10.82292/s5rb-rc48 |
2022-23 (Round 1) Technical Feasibility Assessment |
Dr Evan Wong |
Royal Perth Hospital |
Validation of GMP-compliant manufacture of corneal endothelial cells for injection |
Cell & Tissue Therapies WA |
| https://doi.org/10.82292/yh3s-9n07 |
2022-23 (Round 1) Technical Feasibility Assessment |
Prof Enzo Porrello |
Murdoch Childrens Research Institute |
Evaluating technical feasibility of cGMP production of bioengineered heart tissue to treat heart failure in congenital heart disease |
Centre of Excellence in Cellular Immunotherapy |
| https://doi.org/10.82292/w05g-f869 |
2022-23 (Round 1) Technical Feasibility Assessment |
A/Prof Joshua Ooi |
Monash University |
Manufacture of autologous T regulatory cells modified ex vivo to express T cell receptors for autoimmune disease |
Centre of Excellence in Cellular Immunotherapy |
| https://doi.org/10.82292/gcaa-bf28 |
2022-23 (Round 2) |
Gregory Santamaria |
Cyclotek (Aust) Pty Ltd |
Development of novel fluorinated ligands of fibroblast activation protein, FAP, as diagnostic radiotracers of oncological disorders |
Australian Translational Medicinal Chemistry Facility |
| https://doi.org/10.82292/h09v-qt40 |
2022-23 (Round 2) |
Dr Chengxue Helena Qin |
Monash University |
Novel disease-modifying approach to treat pulmonary hypertension |
Australian Translational Medicinal Chemistry Facility |
| https://doi.org/10.82292/c2nc-hs42 |
2022-23 (Round 2) |
Dr Evan Wong |
Lions Eye Institute, Sir Charles Gairdner Hospital and Royal Perth Hospital |
Validation of GMP-compliant manufacture of corneal endothelial cells for intraocular injection as an alternative to corneal transplantation |
Cell & Tissue Therapies WA |
| https://doi.org/10.82292/7t77-8r16 |
2022-23 (Round 2) |
Dr Steven Suchting |
Emenda Therapeutics Australia Pty Ltd |
Development of SRPK1 kinase inhibitors for osteoarthritis pain |
Centre for Drug Candidate Optimisation |
| https://doi.org/10.82292/vxq8-dk28 |
2022-23 (Round 2) |
A/Prof Joshua Ooi |
Monash University |
Manufacture of autologous T regulatory cells modified ex vivo to express T cell receptors for autoimmune disease |
Centre of Excellence in Cellular Immunotherapy |
| https://doi.org/10.82292/7esc-3t92 |
2022-23 (Round 2) |
A/Prof David Ian Roper FRSC |
University of Warwick,UK |
Drug discovery for bacterial glycosyltransferases to combat AMR using the Monash Fragment Platform (MFP) screening facility |
Monash Fragment Platform |
| https://doi.org/10.82292/ejrx-cv73 |
2022-23 (Round 2) |
A/Prof Ann Kwan |
University of Sydney |
Targeting FtsY for a new class of antibiotics |
Monash Fragment Platform |
| https://doi.org/10.82292/tde2-xa63 |
2022-23 (Round 2) |
Dr Balaji Somasundaram |
Denteric Pty Ltd |
Enabling translation of a therapeutic vaccine candidate against Porphyromonas gingivalis |
National Biologics Facility Queensland Node |
| https://doi.org/10.82292/k6ra-dm24 |
2022-23 (Round 2) |
Ms Reema Bajaj |
Burnet Institute |
Engineering IgG-like ACE2 antivirals against future pathogenic coronavirus events |
National Biologics Facility Queensland Node |
| https://doi.org/10.82292/65qn-ay35 |
2022-23 (Round 2) |
Prof Fabienne Mackay |
QIMR Berghofer Medical Research Institute |
Large-scale production of a TACI-targeting antibody to test its therapeutic efficacy in a preclinical model of chronic lymphocytic leukaemia. |
Protein Expression Facility |
| https://doi.org/10.82292/2f7w-jp96 |
2023-24 (Round 1) |
Dr Steven Petratos |
Monash University |
Development of Integrin αVβ3 Agonists to Promote Remyelination in Multiple Sclerosis |
Australian Translational Medicinal Chemistry Facility |
| https://doi.org/10.82292/41v0-w038 |
2023-24 (Round 1) |
Prof Tom Gonda |
University of South Australia |
Structure-Activity Analysis and Optimisation of Potential MYB-p300 Inhibitors |
Australian Translational Medicinal Chemistry Facility |
| https://doi.org/10.82292/781r-w361 |
2023-24 (Round 1) |
A/Prof Ian Street |
Children's Cancer Institute |
Developing METTL5 Inhibitors for the treatment of paediatric neuroblastoma and adult solid tumours |
Australian Translational Medicinal Chemistry Facility and Centre for Drug Candidate Optimisation |
| https://doi.org/10.82292/9vpx-jc18 |
2023-24 (Round 1) |
Dr Thomas Tapmeier |
Monash University |
Peripherally Restricted NPSR1 Antagonist in Endometriosis |
Australian Translational Medicinal Chemistry Facility and Centre for Drug Candidate Optimisation |
| https://doi.org/10.82292/7tpw-d508 |
2023-24 (Round 1) |
Dr Serena Duchi |
University of Melbourne |
Developing a GMP Compliant Adipose Derived Stem Cell Manufacturing Process for Cartilage Based Stem Cell Therapies |
Cell & Molecular Therapies |
| https://doi.org/10.82292/tp2b-8s57 |
2023-24 (Round 1) |
Dr Rosalind Wilson |
Carpe Vitae Pharmaceuticals |
Development of a novel drug targeting age-related diseases |
Centre for Drug Candidate Optimisation |
| https://doi.org/10.82292/tzwg-5b43 |
2023-24 (Round 1) |
Prof Rachel Codd |
The University of Sydney |
Efficacy and toxicity measures of a new class of iron chelator |
Centre for Drug Candidate Optimisation |
| https://doi.org/10.82292/vd5s-yt78 |
2023-24 (Round 1) |
A/Prof Matthew Piggott |
University of Western Australia and Emyria Ltd |
Hit to lead optimisation of novel drug candidates targeting mental health and neurodegenerative diseases. |
Centre for Drug Candidate Optimisation |
| https://doi.org/10.82292/j8qe-yt55 |
2023-24 (Round 1) |
Dr Jonathan Danon |
The University of Sydney |
Innovative Molecules for Imaging Neuroinflammation |
Centre for Drug Candidate Optimisation |
| https://doi.org/10.82292/34pm-ze18 |
2023-24 (Round 1) |
Dr Willem Joost Lesterhuis |
Telethon Kids Institute |
Small molecule drugs in immuno-oncology |
Centre for Drug Candidate Optimisation |
| https://doi.org/10.82292/ften-d773 |
2023-24 (Round 1) |
Dr Pegah Varamini |
University of Sydney |
Development of new nano-platforms for the treatment of triple negative breast cancer (TNBC). |
Centre for Integrated Preclinical Drug Development |
| https://doi.org/10.82292/3yqb-1104 |
2023-24 (Round 1) |
Dr Natalie Borg |
RMIT University |
Development of novel agents targeting severe viral infections |
CSIRO Biotherapeutics |
| https://doi.org/10.82292/a26z-mj46 |
2023-24 (Round 1) |
A/Prof Andrew Wise |
Bionics Institute |
Optimisation of a therapeutic neurotrophin molecule to enable evaluation in a first in human clinical trial |
CSIRO Biotherapeutics |
| https://doi.org/10.82292/fscs-st66 |
2023-24 (Round 1) |
Dr Aggie Susanti Lawer |
University of Sydney |
Developing Precision Covalent Therapeutics to Target Protein Disulfide Isomerase A6: A Novel and Safer Strategy Against Acute Ischaemic Stroke |
GRIDD Mass Spectrometry Screening and Compounds Australia |
| https://doi.org/10.82292/2mjv-sm96 |
2023-24 (Round 1) |
Dr Sarah Jones |
Monash University |
Fragment screen for E3 ligase inhibitors |
Monash Fragment Platform |
| https://doi.org/10.82292/h0pk-x570 |
2023-24 (Round 1) |
Dr David Jacques |
University of New South Wales |
Developing anti-capsid therapeutics for HTLV-1 |
Monash Fragment Platform |
| https://doi.org/10.82292/bbvh-xb24 |
2023-24 (Round 1) |
Mr Miguel Aguirre |
University of Queensland |
Development of a vaccine to prevent Group A Streptococcus pharyngeal infection |
Protein Expression Facility |
| https://doi.org/10.82292/y7g4-xt28 |
2023-24 (Round 1) |
Dr Sohinee Sarkar |
Murdoch Children’s Research Institute |
A stem cell powered drug discovery pipeline for non-tuberculous mycobacteria |
Stem Cell Disease Modelling & Drug Screening Facility |
| https://doi.org/10.82292/zf1a-rs46 |
2023-24 (Round 1) |
Prof Shane Grey |
Garvan Institute of Medical Research |
Development of a novel anti inflammatory gene therapy for type 1 diabetes |
Sydney Cell and Gene Therapy |
| https://doi.org/10.82292/x678-yt71 |
2023-24 (Round 1) |
A/Prof Garron Dodd |
The University of Melbourne |
Identifying New Targets to Treat Metabolic Disease |
Victorian Centre for Functional Genomics |
| https://doi.org/10.82292/0dz9-w981 |
2023-24 (Round 1) Technical Feasibility Assessment |
Mr David Thomas Kneen |
Celleo Biotech Pty Ltd |
Automated aseptic manufacture of serum eye drops for patients suffering dry eye conditions |
Cell & Tissue Therapies WA |
| https://doi.org/10.82292/371z-db46 |
2023-24 (Round 1) Technical Feasibility Assessment |
Prof Majid Ebrahimi Warkiani |
SMART MCs Pty Ltd |
Biodegradable Microcarriers for Therapeutic Stem Cells: A Feasibility Analysis for Large-Scale Production |
Cell & Tissue Therapies WA |
| https://doi.org/10.82292/x1pq-hs83 |
2023-24 (Round 1) Technical Feasibility Assessment |
A/Prof Jason Waithman |
University of Western Australia |
Improving adoptive cell therapy protocols through transcriptional rewiring of T cells |
Cell & Tissue Therapies WA |
| https://doi.org/10.82292/2adk-w783 |
2023-24 (Round 1) Technical Feasibility Assessment |
Prof David Gottlieb |
Western Sydney Local Health District |
Commercial scale up of CMV and EBV specific T-cell manufacturing |
Centre of Excellence in Cellular Immunotherapy (Peter MacCallum Cancer Centre) |
| https://doi.org/10.82292/9s20-b112 |
2023-24 (Round 1) Technical Feasibility Assessment |
Dr Saparna Pai |
James Cook University |
Retrieving short-term memories for tuberculosis treatment |
Q-Gen Cell Therapeutics (QIMR Berghofer) |
| https://doi.org/10.82292/p3j5-5925 |
2023-24 (Round 1) Technical Feasibility Assessment |
Dr Anai Gonzalez Cordero |
Children’s Medical Research Institute |
Developing an ‘allogeneic stem cell-derived photoreceptor cell product’ compatible with good manufacturing practice (GMP) conditions. |
Sydney Cell and Gene Therapy |
| https://doi.org/10.82292/ax43-0433 |
2023-24 (Round 2) |
Dr Rabina Giri |
Mater Research Institute |
Microbiome derived IBD small molecule |
QEDDI |
| https://doi.org/10.82292/6swt-n012 |
2023-24 (Round 2) |
Dr Michael Nafisinia |
Westmead institute for Medical Research |
Enhancing Therapeutic Efficacy: Pioneering Large-Scale Drug Pipeline Development and Testing on PKU Patients' iPSC-Derived Hepatocytes |
ACRF Drug Discovery Centre for Childhood Cancer |
| https://doi.org/10.82292/wmpm-vj58 |
2023-24 (Round 2) |
A/Prof Antoine de Weck |
Children's Cancer Institute |
The druggable transcriptome: Small Molecules inducing Reading Frame Stops (SMIRFS) |
ACRF Drug Discovery Centre for Childhood Cancer |
| https://doi.org/10.82292/bcc9-1p43 |
2023-24 (Round 2) |
Scientia A/Prof Nadeem Kaakoush |
University of New South Wales |
Discovery of novel therapeutic compounds targeting the microbiome-immune axis in ulcerative colitis |
ANU Centre for Therapeutic Discovery |
| https://doi.org/10.82292/cyj5-hc64 |
2023-24 (Round 2) |
Dr Makutiro Masavuli |
Basil Hetzel Institute (BHI) for Translational Health Research |
mRNA vaccine for HCV |
BASE Facility |
| https://doi.org/10.82292/zpce-nm72 |
2023-24 (Round 2) |
Dr Rhys Parry |
University of Queensland |
Self-amplifying RNAs with modified NTPs: a next-generation vaccine and therapeutic platform. |
BASE Facility |
| https://doi.org/10.82292/2smv-hr94 |
2023-24 (Round 2) |
Dr Adam Johnson |
Skin2Neuron |
Development of automated manufacture of hair follicle-derived neuroprecursors for GLP-Tox IND-enabling studies |
Biologics Innovation Facility |
| https://doi.org/10.82292/k8zs-8q56 |
2023-24 (Round 2) |
Dr Rohan Volpe |
WEHI |
Pharmacokinetic profiling of two novel antiviral coronavirus protease inhibitors towards clinical application for COVID-19 and beyond. |
Centre for Drug Candidate Optimisation |
| https://doi.org/10.82292/6w34-4797 |
2023-24 (Round 2) |
Prof Chris Langmead |
Phrenix Therapeutics Pty Ltd |
Pre-candidate selection for novel schizophrenia therapeutics |
Centre for Drug Candidate Optimisation |
| https://doi.org/10.82292/ftvt-cz86 |
2023-24 (Round 2) |
Prof Mohammed Akhter Hossain |
Florey Institute of Neuroscience and Mental Health |
Novel brain peptide receptor analgesics: Accelerated target validation and pre-clinical testing of RXFP3 activators |
Centre for Integrated Preclinical Drug Development |
| https://doi.org/10.82292/03zp-yt46 |
2023-24 (Round 2) |
A/Prof Kathryn Fay Tonissen |
Griffith University |
Characterisation of covalent binders for a potential new drug target in oncology, Carbonic Anhydrase 3 |
Compounds Australia and Mass Spectrometry Screening Platform |
| https://doi.org/10.82292/2172-vv92 |
2023-24 (Round 2) |
Dr Sofia Burgener |
University of Queensland |
Caspase-1 inhibitors for the treatment of inflammatory disease |
Compounds Australia, Queensland Emory Drug Discovery Initiative and Mass Spectrometry Screening Platform |
| https://doi.org/10.82292/gdqh-tz30 |
2023-24 (Round 2) |
Dr Dhuong Nhu |
University of Melbourne |
Bioconjugation and characterisation of novel Antibody-Drug Conjugates for in vivo (mouse) studies targeting breast cancer |
CSIRO Biotherapeutics |
| https://doi.org/10.82292/mbxj-ct59 |
2023-24 (Round 2) |
Dr Ruth Thornton |
Telethon Kids Institute |
Blitz-OM- development of a slow-release anti-biofilm treatment to prevent the need for recurrent grommet surgery |
CSIRO Biotherapeutics |
| https://doi.org/10.82292/9pnp-mc26 |
2023-24 (Round 2) |
A/Prof Danielle Stanisic |
Griffith University |
Manufacturability assessment of a whole parasite malaria vaccine |
CSIRO Biotherapeutics |
| https://doi.org/10.82292/4gdy-fd17 |
2023-24 (Round 2) |
Michael Grant |
Q-Sera Pty Ltd |
RAPClot bioassay validation and optimisation |
CSIRO Biotherapeutics |
| https://doi.org/10.82292/mdm8-ag21 |
2023-24 (Round 2) |
Prof Stephanie Watson |
University of Sydney |
Transforming corneal stem cell-based therapies with innovative bioengineered technologies |
CSIRO Biotherapeutics |
| https://doi.org/10.82292/scb6-0t61 |
2023-24 (Round 2) |
A/Prof Charlene Kahler |
University of Western Australia |
Breaking ceftriaxone resistance in Neisseria gonorrhoeae using an inhibitor of lipid A phosphethanolamine transferase (EptA) |
Monash Fragment Platform |
| https://doi.org/10.82292/8nmp-zn65 |
2023-24 (Round 2) |
A/Prof Greg Arndt |
Children's Cancer Institute |
Hit identification using DEL for the development of small molecule targeted treatment of osteosarcomas |
Monash Fragment Platform |
| https://doi.org/10.82292/eazt-fz05 |
2023-24 (Round 2) |
Dr Natalie Diepenhorst |
Monash University |
Lead discovery for the orphan GPCR, GPR88 |
Monash Fragment Platform |
| https://doi.org/10.82292/mfv6-5051 |
2023-24 (Round 2) |
Dr Lucia Florencia Zacchi |
University of Queensland |
Characterisation of novel antibodies for the treatment of neuropathic pain |
National Biologics Facility |
| https://doi.org/10.82292/c6fn-4v12 |
2023-24 (Round 2) |
Dr Hannah Kelly |
Australian National University |
Improving mRNA vaccines with precision vaccinology |
UNSW RNA Institute |
| https://doi.org/10.82292/y6tz-4436, 10.82509/hz3j-jw23 |
2023-24 (Round 2) |
Dr Louise Robertson |
University of Adelaide |
Next-generation CRISPR therapeutics for autosomal dominant retinitis pigmentosa |
Vector and Genome Engineering Facility and South Australia Genome Editing Facility |
| https://doi.org/10.82292/5m3a-9g17 |
2023-24 (Round 2) Technical Feasibility Assessment |
Dr Sarah Sutherland |
Chris O’Brien Lifehouse |
Exploring the Feasibility of Tumour Infiltrating Lymphocyte (TIL) Therapy in Appendiceal Cancer |
Cell & Molecular Therapies |
| https://doi.org/10.82292/h1ep-zz28 |
2023-24 (Round 2) Technical Feasibility Assessment |
Dr Yvette Wooff |
Australian National University |
Red blood cell-extracellular vesicles to treat retinal degenerative diseases. |
Centre of Excellence in Cellular Immunotherapy |
| https://doi.org/10.82292/xebv-6805 |
2024-25 (Round 1) |
Prof Carl Walkley |
Hudson Institute of Medical Research and Monash University |
Developing new therapies to treat ADAR1 mutant disease. |
ANU Centre for Therapeutic Discovery |
| https://doi.org/10.82292/b9s5-7m04 |
2024-25 (Round 1) |
Dr Chengxue Helena Qin |
Monash University |
Novel disease-modifying approach to treat pulmonary hypertension |
Australian Translational Medicinal Chemistry Facility |
| https://doi.org/10.82292/4wff-yt84 |
2024-25 (Round 1) |
Dr Sheng Yu Ang |
Neuromedicines Discovery Centre (NDC) |
Potent and selective non-hallucinogenic serotonin 2A receptor agonists for the treatment of severe mental health disorders |
Australian Translational Medicinal Chemistry Facility |
| https://doi.org/10.82292/w083-zr74 |
2024-25 (Round 1) |
Dr Mai Ngoc Vu |
University of Melbourne |
Harnessing mRNA Lipid Nanoparticles For Efficient Delivery Of Influenza Monoclonal Antibody Therapeutics |
BASE Facility |
| https://doi.org/10.82292/bdjv-af82 |
2024-25 (Round 1) |
Dr Ioanna Savvidou |
Monash university |
Development of endothelial targeted-CD39 as a novel treatment for micro circulatory thrombosis in stroke and global brain ischaemia. |
Biologics Innovation Facility |
| https://doi.org/10.82292/dq67-xw61 |
2024-25 (Round 1) |
Dr Dannel Yeo |
Centenary Institute |
Tumour infiltrating lymphocyte therapy for appendiceal cancer |
Cell & Molecular Therapies |
| https://doi.org/10.82292/kymr-0n02 |
2024-25 (Round 1) |
Mrs Harsha Gupta |
Cynata Therapeutics Limited |
Development of cryopreserved wound patches with stem cells ready for thawing at point of care |
Cell & Tissue Therapies WA |
| https://doi.org/10.82292/hszt-te09 |
2024-25 (Round 1) |
A/ Prof Willem Joost Lesterhuis |
Kids Research Institute Australia |
Lead-to-candidate optimisation of a small molecule oncology drug |
Centre for Drug Candidate Optimisation |
| https://doi.org/10.82292/2y4k-jn58 |
2024-25 (Round 1) |
Dr Ralph Patrick |
Institute for Molecular Bioscience, The University of Queensland |
Synthesis and Characterization of Transcription Factor Inhibitors for Therapeutic Interventions in Age-Related Conditions |
Centre for Drug Candidate Optimisation and Qld Emory Drug Discovery Initiative |
| https://doi.org/10.82292/9n3a-ma52 |
2024-25 (Round 1) |
A/ Prof Nicholas Veldhuis |
Monash Institute of Pharmaceutical Sciences |
Assessing efficacy of new generation analgesic nanoparticles for osteoarthritic pain |
Centre for Integrated Preclinical Drug Development |
| https://doi.org/10.82292/wzy9-rj34 |
2024-25 (Round 1) |
A/ Prof Richard Gordon |
Queensland University of Technology |
Screening and validation of novel therapeutic agents for inflammation resolution and neuroprotection in Parkinson's disease |
Compounds Australia |
| https://doi.org/10.82292/4wg2-2a33 |
2024-25 (Round 1) |
Dr Nicole van Bergen |
Murdoch Children’s Research Institute |
High-throughput drug screening for paediatric epilepsy due to pathogenic variants in CDKL5 |
Compounds Australia and Stem Cell Disease Modelling & Drug Screening Facility |
| https://doi.org/10.82292/1ekw-8q64 |
2024-25 (Round 1) |
Dr Rosemary Cater |
Institute for Molecular Bioscience (UQ) |
FLVCR2 inhibition for the treatment of glioblastoma |
Compounds Australia, Qld Emory Drug Discovery Initiative and IBG-Nathan Mass Spec Facility |
| https://doi.org/10.82292/memn-sy04 |
2024-25 (Round 1) |
Prof Peter Currie |
Australian Regenerative Medicine Institute |
Development of NAMPT-cif Fc fusion for treatment of muscle disease |
CSIRO Biotherapeutics |
| https://doi.org/10.82292/2paq-nn75 |
2024-25 (Round 1) |
A/ Prof Michelle Wykes |
QIMR Berghofer/ Fovero Therapeutics |
Novel therapy for cancer |
CSIRO Biotherapeutics |
| https://doi.org/10.82292/z7mj-0359, 10.82509/5952-mk69 |
2024-25 (Round 1) |
Dr Aude Dorison |
Murdoch Children’s Research Institute |
Screening for new treatments for glomerular disease with a new stem cell reporter line |
Drug discovery Facility. Phenomics Australia Nodes: Induced Pluripotent Stem Cell Derivation & CRISPR Gene Editing Facility |
| https://doi.org/10.82292/4zhk-sn82 |
2024-25 (Round 1) |
Dr Brian Liddicoat |
exteRNA |
Targeting novel RNA biology in cancer |
Monash Fragment Platform |
| https://doi.org/10.82292/kyaa-m164 |
2024-25 (Round 1) |
Dr Rebecca Nisbet |
Florey Institute of Neuroscience and Mental Health |
Development of an active immunotherapy for Alzheimer's disease |
mRNA CORE |
| https://doi.org/10.82292/9mfa-s753 |
2024-25 (Round 1) |
Dr Frances Evesson |
Children’s Medical Research Institute and Sydney Children’s Hospitals Network |
Therapeutic possibilities for PYROXD1 myopathy |
mRNA CORE |
| https://doi.org/10.82292/dyqt-9y77 |
2024-25 (Round 1) |
Prof Bryan Day |
QIMR Berghofer Medical Research Institute |
Novel Eph Receptor Antibody Drug Conjugate Therapy Development for the Treatment of Paediatric Brain Cancer |
National Biologics Facility |
| https://doi.org/10.82292/1pya-8686 |
2024-25 (Round 1) |
Prof Katherine Andrews |
Griffith University |
Screening chemically diverse compounds that represent untested chemical space for activity against Plasmodium malaria parasites |
National Drug Discovery Centre |
| https://doi.org/10.82292/jwz9-cx37 |
2024-25 (Round 1) |
Dr Stephan Brouwer |
Institute for Molecular Bioscience (UQ) |
Development of an optimised vaccine formulation to prevent Group A Streptococcus infection |
Protein Expression Facility |
| https://doi.org/10.82292/4eb3-8w96 |
2024-25 (Round 1) |
A/ Prof Zi (Sophia) Gu |
University of New South Wales |
Development of a mRNA nanoparticle formulation for low back pain treatment |
UNSW RNA Institute |
| https://doi.org/10.82292/1298-mm91 |
2024-25 (Round 1) |
Dr Kavitha Gowrishankar |
Kids Research Institute, Children’s Hospital Westmead |
EphA2 Chimeric Antigen Receptor (CAR) T cell Therapy for Children with Bone Tumours: A Phase I Clinical Trial |
Sydney Cell and Gene Therapy |
| https://doi.org/10.82292/ghqt-pw57 |
2024-25 (Round 1) |
Dr Bijay Dhungel |
Centenary Institute |
Muscle-targeted adeno-associated viruses for safer gene therapy |
Vector and Genome Engineering Facility |
| https://doi.org/10.82292/9tyt-vv45 |
2024-25 (Round 1) Technical Feasibility Assessment |
A/ Prof Elizabeth Ng |
Murdoch Children’s Research Institute |
Autologous haematopoietic stem cells, moving transplantation into the 21st century |
Cell Therapies Pty Ltd |
| https://doi.org/10.82292/3a7b-dy07 |
2024-25 (Round 2) |
Dr Nicholas Hunt |
Endo Axiom |
A GLP repeat dose oral toxicity study of Endo Axiom’s inverse vaccine for prevention of type 1 diabetes |
Agilex Biolabs |
| https://doi.org/10.82292/5jb0-f025 |
2024-25 (Round 2) |
A/Prof Michelle Wykes |
QIMR Berghofer/ Fovero Therapeutics |
Novel therapy for cancer |
Agilex Biolabs |
| https://doi.org/10.82292/mc5c-z687 |
2024-25 (Round 2) |
Prof Christopher Sweeney |
University of Adelaide |
SAi001 Pharmacokinetic Bridging Study |
Agilex Biolabs |
| https://doi.org/10.82292/tcsk-8z68 |
2024-25 (Round 2) |
Dr Thomas Tapmeier |
Monash University |
Peripherally Restricted NPSR1 Antagonist in Endometriosis |
Australian Translational Medicinal Chemistry Facility |
| https://doi.org/10.82292/hb1z-ar16 |
2024-25 (Round 2) |
Dr Yi David Ju |
La Trobe University |
In Vivo mRNA CAR T Cell Engineering via Targeted Lipid Nanoparticles |
BASE Facility |
| https://doi.org/10.82292/fbwx-c890 |
2024-25 (Round 2) |
Dr Frankie Butera |
Murdoch Children’s Research Institute |
Assessing the pharmacokinetic profile of small molecules to promote cardiomyocyte specific proliferation |
Centre for Drug Candidate Optimisation |
| https://doi.org/10.82292/x821-fs14 |
2024-25 (Round 2) |
Dr Stephen Huang |
Mater Research Institute |
In vivo macrophage modulation |
Centre for Integrated Preclinical Drug Development , National Biologics Facility |
| https://doi.org/10.82292/vb12-8g43 |
2024-25 (Round 2) |
Dr David Leaver |
Charles Sturt University |
Targeting sterol metabolism as a way to kill parasitic worms |
Compounds Australia, ANU Centre for Therapeutic Discovery |
| https://doi.org/10.82292/jc4g-4q71 |
2024-25 (Round 2) |
Dr Melanie Robitaille |
University of Queensland |
TRPC3 inhibitors for the treatment of cardiac disease |
Compounds Australia, QEDDI, IBG-Nathan Mass Spec Facility |
| https://doi.org/10.82292/bj7v-1986 |
2024-25 (Round 2) |
Professor Claudine Bonder |
University of South Australia |
Advancing a ‘first-in-class’ monoclonal antibody to combat cancer. |
CSIRO Biotherapeutics |
| https://doi.org/10.82292/9cy6-tf80 |
2024-25 (Round 2) |
Dr Joanne Casey |
Immuron Limited |
Design, Scale-up and Manufacturability of a Safe and Effective TcdB Immunogen to Support the Development of an Oral Therapy for the Treatment of Clostridioides difficile infections. |
CSIRO Biotherapeutics |
| https://doi.org/10.82292/g7eh-0107 |
2024-25 (Round 2) |
Dr Maria Garone |
Murdoch Children's Research Institute |
Development of a high-throughput drug screening platform for paediatric brain tumours using advanced cancer-brain organoid models |
Drug Discovery Facility |
| https://doi.org/10.82292/jfp4-6773, https://ror.org/042gz1a70 |
2024-25 (Round 2) |
Dr Rudrarup Bhattacharjee |
University of Adelaide |
Deciphering the mechanism of Rubinstein-Taybi Neurodevelopmental Syndrome and screening new therapeutic options |
Functional Genomics SA , Monash Proteomics & Metabolomics Platform (Bioplatforms Australia) |
| https://doi.org/10.82292/mbr4-xx28 |
2024-25 (Round 2) |
Professor Gregory Cook |
Queensland University of Technology |
Development of anti-virulence strategies to combat MDR gram-negative pathogens |
IBG- Mass Spectrometry Screening Platform |
| https://doi.org/10.82292/7k4v-gk61 |
2024-25 (Round 2) |
Prof Joseph Trapani |
University of Melbourne |
Drugs that block lymphocyte perforin - focused immunosuppressive agents for auto-immune and post-infectious pathologies |
Medicines Manufacturing Innovation Centre |
| https://doi.org/10.82292/d5hz-vz87 |
2024-25 (Round 2) |
Dr Gilbert Song |
University of Queensland |
Discovery of MyD88 inhibitors for novel anti-inflammatory and anti-cancer therapy |
Monash Fragment Platform |
| https://doi.org/10.82292/tsjr-g881 |
2024-25 (Round 2) |
Dr Diyana Hassanel |
Garvan Institute of Medical Research |
Development of targeted mRNA vaccines for liver cancer |
mRNA CORE |
| https://doi.org/10.82292/b8dx-kd78 |
2024-25 (Round 2) |
Dr Clare Slaney |
Peter MacCallum Cancer Centre |
Overcoming the heterogeneity of cancer antigen expression with an mRNA vaccine and precision LNP delivery. |
mRNA CORE |
| https://doi.org/10.82292/pbek-9241 |
2024-25 (Round 2) |
Dr Behnaz Heydarchi |
WEHI |
Advancing a novel therapy for the prevention of haemolytic disease of the foetus and newborn |
National Biologics Facility |
| https://doi.org/10.82292/vdtg-x225 |
2024-25 (Round 2) |
Dr Mehdi Tabar |
Centenary Institute |
Epigenetic-directed drug development for type I interferonopathies |
National Drug Discovery Centre |
| https://doi.org/10.82292/4zed-e944 |
2024-25 (Round 2) |
Prof Rebecca Ritchie |
Monash University |
Optimisation of a new class of inflammation-resolving GPCR agonists for the treatment of Heart Failure with preserved Ejection Fraction (HFpEF) |
National Drug Discovery Centre |
| https://doi.org/10.82292/exbs-dd58, https://ror.org/042gz1a70 |
2024-25 (Round 2) |
Dr Zhi Ying Kho |
Monash University |
High-Throughput Phenotypic and Target-Based Profiling of Novel Antimicrobials Using Imaging and Proteomics |
National Drug Discovery Centre, Monash Proteomics & Metabolomics Platform (Bioplatforms Australia) |
| https://doi.org/10.82292/j5ja-e549 |
2024-25 (Round 2) |
Dr Julie Monk |
Resseptor Therapeutics |
Preparation of ADC and Radiotheranositics from our Nvel Covalently Binding T Cell Receptor Against Tumour-Associated Peptide–MHC Complex |
Protein Expression Facility |
| https://doi.org/10.82292/9jdh-ny35, https://ror.org/042gz1a70 |
2024-25 (Round 2) |
Dr Steve Dingwall |
University of Queensland |
Bi-specific proteins for the enhancement of pluripotent stem cell derived heart muscle grafts |
Protein Expression Facility, Metabolomics Australia (Bioplatforms Australia) |
| https://doi.org/10.82292/d61r-9h72 |
2024-25 (Round 2) |
Dr Keith Sia |
Children’s Cancer Institute |
Development of a novel METTL1-specific PROTAC protein degrader |
Recombinant Products Facility, ACRF Drug Discovery Centre for Childhood Cancer |
| https://doi.org/10.82292/f721-2980 |
2024-25 (Round 2) |
Dr Charles Bailey |
Centenary Institute |
Improving the accessibility of adeno-associated virus (AAV) gene therapy |
UNSW RNA Institute |
| https://doi.org/10.82292/9p16-cd72 |
2024-25 (Round 2) |
Prof Colin Pouton |
Monash University |
Optimisation of AAK1 gene knockdown for treatment of chronic pain |
UNSW RNA Institute |
| https://doi.org/10.82292/a82n-7s47 |
2024-25 (Round 2) |
Dr Lipin Loo |
University of Sydney |
Optimising Scale-Up Manufacturing for Cutting-Edge mRNA Pain Relief |
UNSW RNA Institute |
| https://doi.org/10.82292/qa2k-0190 |
2024-25 (Round 2) |
Dr Zohaib Rana |
Fold AI (RNAFold.AI Pty Ltd) |
Targeting Pathogenic Genes in Spinocerebellar Ataxia Using Novel Antisense Oligonucleotides |
UNSW RNA Institute |
| https://doi.org/10.82292/59hx-0x76 |
2024-25 (Round 2) Technical Feasibility Assessment |
Dr Saparna Pai |
TAARA Therapeutics Pty Ltd |
Retrieving short-term memories for treatment of post-TB lung disease |
Q-Gen Cell Therapeutics (QIMR Berghofer) |
| https://doi.org/10.82292/d6sy-qj19, https://ror.org/042gz1a70 |
2025-26 (Round 1) |
Dr Richard Foitzik |
Inosi Therapeutics |
IRAP Inhibitor Manufacturing |
ABINITIO, Australian Genome Research Facility (Bioplatforms Australia) |
| https://doi.org/10.82292/8m4q-w475 |
2025-26 (Round 1) |
Dr Amila Suraweera |
Queensland University of Technology |
Optimisation of a novel small molecule inhibitor for the treatment of lung cancer |
Australian Translational Medicinal Chemistry Facility |
| https://doi.org/10.82292/367r-3672 |
2025-26 (Round 1) |
Dr Kevin Sek |
Peter MacCallum Cancer Centre |
Developing the next generation of cancer mRNA therapeutics |
BASE Facility |
| https://doi.org/10.82292/p1cx-tq96 |
2025-26 (Round 1) |
Chika Prisca Zumuk |
QIMR, Berghofer/ University of Queensland. |
Combatting Schistosomiasis through mRNA-based Transmission blocking vaccines |
BASE Facility |
| https://doi.org/10.82292/v67t-zg84 |
2025-26 (Round 1) |
A/Prof Iain Duggin |
University of Technology Sydney |
Scaling up the manufacture of an mRNA vaccine for the prevention of urinary tract infection |
Biologics Innovation Facility, Recombinant Products Facility, RNA Institute |
| https://doi.org/10.82292/cx49-d747 |
2025-26 (Round 1) |
Dr Mitali Sarkar-Tyson |
University of Western Australia |
Advanced Optimisation of Antivirulence Compounds Against Bacterial Pathogens |
Centre for Drug Candidate Optimisation |
| https://doi.org/10.82292/16ph-nh49 |
2025-26 (Round 1) |
Dr Daryl Ariawan |
Macquarie University |
Next-Generation Small Molecules for Alzheimer’s Therapy |
Centre for Drug Candidate Optimisation |
| https://doi.org/10.82292/rs6v-tw49 |
2025-26 (Round 1) |
Professor Rachel Codd |
University of Sydney |
Pharmacokinetics of Next-Generation Iron Chelators |
Centre for Drug Candidate Optimisation, National Deuteration Facility |
| https://doi.org/10.82292/dteg-qw42 |
2025-26 (Round 1) |
Ms Alison Roennfeldt |
University of Adelaide |
Novel Small Molecule FIH Inhibitors for Treatment of Metabolic Disease |
Centre for Drug Candidate Optimisation, Queensland Emory Drug Discovery Initiative |
| https://doi.org/10.82292/wdbf-gm92 |
2025-26 (Round 1) |
Dr Kiymet Bozaoglu |
Murdoch Children’s Research Institute |
Using patient-derived stem cell models to identify new therapies for NF1 Neurodevelopmental Disorders |
Compounds Australia, Drug Discovery Facility |
| https://doi.org/10.82292/dcge-4y22 |
2025-26 (Round 1) |
Dr Jordan Wright |
Murdoch Children's Research Institute |
Discovery of new treatments for brain development disorders linked to epigenetic regulatory genes |
Compounds Australia, Drug Discovery Facility, Victorian Centre for Functional Genomics |
| https://doi.org/10.82292/ved0-ge05 |
2025-26 (Round 1) |
Dr Siyang Ding |
La Trobe University |
Development of a high-throughput phenotypic screen for lysosomal storage disorders |
Compounds Australia, National Drug Discovery Centre |
| https://doi.org/10.82292/9pqz-k845 |
2025-26 (Round 1) |
Dr Ben Wylie |
UWA Centre for Child Health Research |
Developing a biomaterial for intra-operative delivery of mRNA therapeutics targeting the tumour microenvironment |
CSIRO Biotherapeutics |
| https://doi.org/10.82292/djzx-gw58 |
2025-26 (Round 1) |
Professor Nicodemus Tedla |
University of New South Wales |
Development of a novel treatment option for post-sepsis acute lung injury (ALI) |
CSIRO Biotherapeutics |
| https://doi.org/10.82292/a6d5-nf15 |
2025-26 (Round 1) |
Dr Stefka Tasheva |
University of Adelaide |
Developing Precision Medicine Therapies for PCDH19-Clustering Epilepsy |
Functional Genomics SA |
| https://doi.org/10.82292/pcp8-zf86 |
2025-26 (Round 1) |
Mrs Aneta Nash |
ThyX Pty Ltd |
Development and Assessment of Levothyroxine Implant |
Medicines Manufacturing Innovation Centre |
| https://doi.org/10.82292/a6kd-2y46 |
2025-26 (Round 1) |
Professor Greg Monteith |
University of Queensland |
Development of an Oral Solid Dosage Formulation of Novel Prostate Cancer TRPV6 Inhibitor QED-203 |
Medicines Manufacturing Innovation Centre |
| https://doi.org/10.82292/83n3-wk32 |
2025-26 (Round 1) |
Dr Travis Stiles |
Novoroo Bioscience Pty Ltd |
LRP1 Antagonist to Block Interneuronal Spread of Tau in Alzheimer's Disease |
Monash Fragment Platform |
| https://doi.org/10.82292/frhp-5219 |
2025-26 (Round 1) |
Dr Gabriel Duette |
WEHI |
Developing immunotherapies to enhance CD8 T-cell-mediated clearance of HIV-1-infected cells |
mRNA CORE |
| https://doi.org/10.82292/1gb6-8028 |
2025-26 (Round 1) |
Dr Adam Thomas |
Burnet Institute |
Developing the first multi-species malaria vaccine to provide worldwide protection |
mRNA CORE |
| https://doi.org/10.82292/9nvw-ps38 |
2025-26 (Round 1) |
Dr Grace Mennen |
Monash Institute of Pharmaceutical Science |
Development of Novel Small Molecules for Therapeutic Intervention in Pulmonary Arterial Hypertension (PAH) |
National Drug Discovery Centre |
| https://doi.org/10.82292/see7-kg74 |
2025-26 (Round 1) |
Professor James Hudson |
QIMR Berghofer |
New Generation Specific Epigenetic Inhibitors for Heart Failure |
National Drug Discovery Centre |
| https://doi.org/10.82292/n7te-z623 |
2025-26 (Round 1) |
Dr Adam Johnson |
Skin2Neuron |
Aseptic process simulation runs enabling clinical manufacture of Primaverah for Phase 1/2A clinical use |
Q-Gen Cell Therapeutics (QIMR Berghofer) |
| https://doi.org/10.82292/7rzm-yx25 |
2025-26 (Round 1) |
Dr Shea Carter |
QIMR Berghofer |
Novel Small Molecule G9a Inhibitors for Treating Colon and Liver Cancers |
QEDDI, Protein Expression Facility |
| https://doi.org/10.82292/tcmp-8860 |
2025-26 (Round 1) |
A/ Prof Arnold Lining Ju |
University of Sydney |
Regulation of Adenovirus–Protein Interfaces as a Therapeutic Strategy in Thrombosis |
Recombinant Products Facility |
| https://doi.org/10.82292/ze94-z580 |
2025-26 (Round 1) |
Dr Rodrigo Maron Carlessi |
Curtin Medical Research Institute |
A Programmable RNA Therapy Platform to Treat Liver Cancer |
RNA Innovation Foundry |
| https://doi.org/10.82292/gw81-9r91 |
2025-26 (Round 1) |
Dr Shadabul Haque |
Medicines Manufacturing Innovation Centre |
Development of an Inhaled siRNA Therapeutic Targeting TNF-α for Pulmonary Inflammation |
UNSW RNA Institute |
| https://doi.org/10.82292/zgqk-dk56 |
2025-26 (Round 1) |
Dr Edmund Yin Man Chung |
University of Sydney |
In-vivo generation of chimeric antigen receptor (CAR) T-cells using lipid nanoparticles to treat autoimmune kidney disease |
UNSW RNA Institute |
| https://doi.org/10.82292/2qy1-s306 |
2025-26 (Round 1) |
A/Prof Colm Keane |
University of Queensland |
BrainCAR19 Study - Treatment of relapsed Primary Brain Lymphoma with CD19 directed CAR-T cells |
Sydney Cell and Gene Therapy |
| https://doi.org/10.82292/t8w6-7q06 |
2025-26 (Round 1) |
Professor Arnold Lining Ju |
University of Sydney |
Comparative Investigation of Adenovirus and Adeno-Associated Virus Protein Interfaces in the Context of Thrombosis |
Vector and Genome Engineering Facility, Recombinant Products Facility |
| https://doi.org/10.82292/hbrw-rw97 |
2025-26 (Round 1) Technical Feasibility Assessment |
A/Prof Shireen Lamande |
Murdoch Children's Research Institute (MCRI) |
Products for Cartilage and Bone Repair using Human Induced Pluripotent Stem Cell-Derived Organoids and Decellularized Organoid Scaffolds |
Cell Therapies Pty Ltd |
| https://doi.org/10.82292/ppsx-ea59 |
2025-26 (Round 2) |
Professor Wendy Gold |
1 The School of Medical Sciences, the University of Sydney; 2 Kids Neuroscience Centre, Kids Research, Sydney Children’s Hospital Network |
Transformational Drug Discovery for TAOK1 Neurodevelopmental Disorder |
ACRF Drug Discovery Centre for Childhood Cancer |
| https://doi.org/10.82292/fa5q-p066 |
2025-26 (Round 2) |
Professor Dipti Talaulikar |
Australian National University |
High-Throughput Drug Sensitivity Screening in Multiple Myeloma |
ANU Centre for Therapeutic Discovery |
| https://doi.org/10.82292/tm71-9d80 |
2025-26 (Round 2) |
A/Prof David Croucher |
Garvan Institute of Medical Research |
Development of a selective inhibitor of metastatic relapse |
Australian Translational Medicinal Chemistry Facility |
| https://doi.org/10.82292/8avc-hd40 |
2025-26 (Round 2) |
Dr Natalee Newton |
The School of Chemistry and Molecular Biosciences, The University of Queensland |
Broad-spectrum Japanese Encephalitis virus vaccines using ancestral state reconstruction |
BASE Facility |
| https://doi.org/10.82292/jxdp-7k70 |
2025-26 (Round 2) |
Dr Seen Ling Sim |
The University of Queensland, Frazer Institute, Experimental Dermatology group |
Dual-Action mRNA Therapy for RDEB: Restoring Skin Integrity and Reducing Chronic Itch |
BASE Facility |
| https://doi.org/10.82292/xgb4-v927 |
2025-26 (Round 2) |
Dr Hannah Kelly |
Australian National University |
Improving mRNA vaccines for malaria with precision vaccinology |
BASE Facility |
| https://doi.org/10.82292/vfw0-3729 |
2025-26 (Round 2) |
Professor Stephanie Watson OAM |
The University of Sydney |
Developing a GMP Compliant Manufacturing Process for Sight Lens, a cultured Limbal Epithelial Stem Cell Device |
Cell & Molecular Therapies |
| https://doi.org/10.82292/1qss-3291 |
2025-26 (Round 2) |
Dr John W Scott |
Monash University |
Development of a clinical-grade CAMKK2 inhibitor for the treatment of castration-resistant prostate cancer |
Centre for Drug Candidate Optimisation |
| https://doi.org/10.82292/w057-a673 |
2025-26 (Round 2) |
Dr Annaliese Dillon |
Monash University |
Development of a New, Irresistible medicines for Malaria |
Centre for Drug Candidate Optimisation |
| https://doi.org/10.82292/ja6n-cb31 |
2025-26 (Round 2) |
Dr Bliss Cunningham |
The University of Melbourne |
Advancing development of an antibiotic potentiator therapeutic |
Centre for Drug Candidate Optimisation, Centre for Integrated Preclinical Drug Development |
| https://doi.org/10.82292/qwex-rn19 |
2025-26 (Round 2) |
Dr Steven Suchting |
Emenda Therapeutics Australia Pty Ltd |
Development of intra-articular SRPK1/CLK1 inhibitors for osteoarthritis pain |
Centre for Drug Candidate Optimisation, Centre for Integrated Preclinical Drug Development |
| https://doi.org/10.82292/f0bz-p244 |
2025-26 (Round 2) |
Professor Jana Vukovic |
The University of Queensland |
GP130 Agonists for the treatment of brain and spinal cord injury |
Centre for Drug Candidate Optimisation, Centre for Integrated Preclinical Drug Development, Queensland Emory Drug Discovery Initiative |
| https://doi.org/10.82292/fzv4-0246 |
2025-26 (Round 2) |
Dr Sasanan Trakansuebkul |
Children's Cancer Institute |
Multiplexed Evaluation of Splice‑Site Selectivity for RNA‑Targeted Therapeutics |
Compounds Australia, ACRF Drug Discovery Centre for Childhood Cancer |
| https://doi.org/10.82292/z5a2-6610, https://ror.org/042gz1a70 |
2025-26 (Round 2) |
Dr Emily Grace |
Flinders University |
Discovery of Prophage-Inducing Compounds as a Novel Strategy for Targeted Antibacterial Therapy |
Compounds Australia, South Australian Genomics Centre (Bioplatforms Australia) |
| https://doi.org/10.82292/r0bq-sb12 |
2025-26 (Round 2) |
Professor Sarah Vreugde |
Adelaide University |
Assessing the manufacturability of a new probiotic species |
CSIRO Biotherapeutics |
| https://doi.org/10.82292/rcg2-m392 |
2025-26 (Round 2) |
Associate Professor Natalie Borg |
RMIT University |
Development of anti-viral agents targeting severe viral infections |
CSIRO Biotherapeutics |
| https://doi.org/10.82292/jhsk-k519, https://ror.org/042gz1a70 |
2025-26 (Round 2) |
Dr Thomas Iosifidis |
The Kids Research Institute Australia |
Target Identification for Small molecule Therapeutics in Asthma |
Drug Target Identification, Australian Genome Research Facility (Bioplatforms Australia) |
| https://doi.org/10.82292/fr2c-kj19 |
2025-26 (Round 2) |
Dr Stuart Mudge |
Lateral Pharma Pty Ltd |
Scale-up of LAT9997 as a treatment for chronic neuropathic pain |
Medicines Manufacturing Innovation Centre |
| https://doi.org/10.82292/n3qs-w979 |
2025-26 (Round 2) |
Dr Manuela Jörg |
Monash University |
Development of pan-flaviviral protease inhibitors |
Monash Fragment Platform |
| https://doi.org/10.82292/85bw-r503 |
2025-26 (Round 2) |
Dr Nancy Wang |
Murdoch Children's Research Institute |
Developing a Salmonella combination vaccine for protection against enteric fever and invasive salmonellosis |
mRNA CORE |
| https://doi.org/10.82292/jq1n-xt81 |
2025-26 (Round 2) |
Dr Katherine Audsley |
Beavis Laboratory, Cancer Immunology Research Division, Peter MacCallum Cancer Centre |
Enhancing CAR-T cell therapy with mRNA vaccination |
mRNA CORE |
| https://doi.org/10.82292/3c8m-gk58 |
2025-26 (Round 2) |
Dr Phillip Pymm |
WEHI |
mRNA LNP vaccine design for endemic and emerging Henipaviral diseases. |
mRNA CORE |
| https://doi.org/10.82292/drng-7d97 |
2025-26 (Round 2) |
Dr Li-Jin Chan |
WEHI |
mRNA-LNP vaccines targeting multiple stages of the malaria parasite lifecycle |
mRNA CORE |
| https://doi.org/10.82292/az7h-ra31 |
2025-26 (Round 2) |
Dr Stefanie Buchholz |
Griffith University |
Development of a Continuous Bioprocessing Platform for Antibody Purification from CHO Supernatant |
National Biologics Facility |
| https://doi.org/10.82292/69cg-xj40 |
2025-26 (Round 2) |
Associate Professor Fernando S. F. Guimaraes |
The University of Queensland |
De Novo Antibody Generation Against Glycosylated Cancer Antigens for Next-Generation Immunotherapies |
National Biologics Facility, BASE Facility |
| https://doi.org/10.82292/w5qb-2h72 |
2025-26 (Round 2) |
Dr Gabriel Reis Ferreira |
Intelligence Center in Emerging and Neglected Tropical Conditions (CIATEN) |
RNA-Based Nanotechnology for the Control of Leishmania |
UNSW RNA Institute |
| https://doi.org/10.82292/rsc8-0w30 |
2025-26 (Round 2) |
Dr Kelsie Raspin |
Menzies Institute for Medical Research, University of Tasmania |
Using zebrafish to assess the potential of mitochondrial-associated genes as therapeutic targets for metastatic cancer |
Vector and Genome Engineering Facility |
| https://doi.org/10.82292/32dr-2g49, https://ror.org/042gz1a70 |
2025-26 (Round 2) |
Dr Jennilee Davidson |
Macquarie University |
Advanced gene therapy optimisation for ALS and FTD |
Vector and Genome Engineering Facility, StemCore (Bioplatforms Australia) |
| https://doi.org/10.82292/7vvr-0910 |
2025-26 (Round 2) |
Associate Professor Fabrice Jaffré |
Australian Regenerative Medicine Institute, Monash University |
Discovery of new therapies for hypertrophic cardiomyopathy in Noonan syndrome using a hiPSC-based high-throughput drug screening platform |
Victorian Centre for Functional Genomics |
